In the US, 90% of the one million annual hospitalizations for heart failure (HF) are due to volume overload.
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removed with diuretics. Ultrafiltration removes fluid with a sodium concentration similar to that of plasma, so that approximately 150mmol of sodium are withdrawn with each liter of ultrafiltrate. In contrast, the urine of patients with heart failure is hypotonic compared with plasma and the 50mmol of sodium usually present in 1 liter of urine increases to only 100mmol with furosemide administration. 12 The different amounts of sodium removed with similar amounts of fluid account for the differential effects of ultrafiltration and diuretics on neurohormonal responses, which in turn will result in differing renal sodium and water reabsorption.
Among 32 NYHA class II-IV hypervolemic HF patients, baseline 24-hour diuresis and natriuresis were inversely correlated with neurohormone levels and renal perfusion pressure. 13 The response to ultrafiltration ranged from neurohormonal activation and reduction of diuresis in patients with the mildest hypovolemia and urine output greater than 1,000ml per 24 hours to neurohormonal inhibition and enhanced diuresis and natriuresis in those with the most severe volume overload and urine output less than 1,000ml per 24 hours. 13 Decreases in norepinephrine levels were proportional to the enhancement of diuresis. Thus, subtraction of total body water uncovers enough cardiac reserve to increase cardiac output and attenuate neurohormonal activation. Benefits are then maintained because the enhanced diuresis improves norepinephrine clearance from the circulation. 11 The earliest effect of ultrafiltration may be the reduction of the extravascular pulmonary fluid, with a subsequent decrease in pulmonary extravascular resistance, improvement of ventilation and gas exchange, and a decrease in hypoxia-induced vasoconstriction.
Ultrafiltration itself, via baroreceptor-mediated reflexes, may re-set neurohormonal activation, which may explain the intermediate-and
long-term benefits of ultrafiltration. 11 The removal of myocardial depressant factors may also occur. 14 In 36 patients with acutely decompensated HF, ultrafiltration was associated with increased cardiac index and oxygenation status, decreased pulmonary artery pressure and vascular resistance, and a reduced requirement for inotropes. 15 It is unknown whether the clinical benefits of ultrafiltration translate into improved survival. In decompensated HF patients, ultrafiltration has been used predominantly after diuretics have failed or in the presence of acute renal failure. Earlier utilization of ultrafiltration can expedite and maintain the compensation of acute HF by simultaneously reducing volume overload without causing intravascular volume depletion and re-establishing acid base and electrolyte balance.
However, overly aggressive ultrafiltration in patients with decompensated HF can convert non-oliguric renal dysfunction into oliguric renal failure by increasing neurohormonal activation and decreasing renal perfusion pressure with minimal opportunity for recovery of renal function.
Ultrafiltration Therapies
The continuous ultrafiltration techniques include continuous hemofiltration in the arterial-venous (CAVH) or veno-venous mode (CVVH) and slow continuous ultrafiltration (SCUF) in arterial-venous or veno-venous modes. 16 Using a large-bore catheter inserted into the femoral artery and the patient's own blood pressure, arterial blood is delivered to a hemofilter. Systemic blood pressure provides the driving force to achieve sufficient blood flow. When hydrostatic pressure exceeds oncotic pressure, ultrafiltrate is generated.
Ultrafiltrate drains by gravity through tubing into a collection bag, creating mild negative pressure in the filter's blood chamber, favoring further ultrafiltration. 16 With SCUF, replacement volumes are much lower than with CAVH. Recently, extracorporeal blood pumps have been re-introduced to eliminate the need for an arterial-venous pressure gradient and permit veno-venous vascular access (CVVH). 17 Until the introduction of simplified intermittent peripheral veno-venous ultrafiltration techniques, CVVH and SCUF were the recommended therapies for the more critically ill, hypotensive HF patients. 17 As CVVH requires an extracorporeal blood pump, air embolism and blood loss can occur. In SCUF, air embolism is uncommon and blood loss With intermittent isolated ultrafiltration, the blood is pumped through a filter by an extracorporeal blood pump aided either by suction applied to the ultrafiltrate compartment (negative pressure) or from resistance induced in the venous line (positive pressure). Due to the pump, a dual-lumen veno-venous catheter will generate a blood flow of 500-1,000ml/hour. Slower rates over longer periods of time improve hemodynamic tolerance. 19 Intermittent isolated ultrafiltration is effective in removing salt and water in hypervolemic patients with moderate and severe HF. 19 Many patients regain responsiveness to diuretics after one or more ultrafiltration treatment, suggesting that untapped cardiac functional reserve is recruited by ultrafiltration. 19 Ascites, edema, dyspnea, and hyponatremia may improve. Plasma volume falls and oncotic pressure rises. 19 Ultrafiltration increases transcapillary gradient and plasma colloid osmotic pressure. 8 This increase is maximal during the first 60 minutes of ultrafiltration and then levels If the ultrafiltration rate is limited to 500-1,000ml/hour for only a few hours, heart rate, blood pressure, and systemic vascular resistance remain unchanged. 10 Cardiac output either rises or remains stable. Pulmonary capillary wedge pressure is unchanged or decreased. Right atrial pressure and pulmonary vascular resistance fall. An improved ejection fraction and a decreased radiographic cardiothoracic ratio have also been described. 10 Advantages of intermittent isolated ultrafiltration include the avoidance of an arterial puncture and the short exposure to systemic anticoagulation.
Disadvantages include the need for dialysis equipment and personnel, and the removal of large amounts of fluid in a short time period. Hemorrhage from anticoagulation and extracorporeal blood pump complications, such as air embolism, can occur.
Intermittent isolated ultrafiltration has been described in more than 100 patients with NYHA class IV refractory HF. 20 Of 52 patients treated with slow isolated ultrafiltration, 13 died in less than one month during treatment (non-responders), 24 experienced both cardiac and renal improvement (responders) for either less than three (n=6) or more than three months Restoration of diuresis and natriuresis after intermittent ultrafiltration identified patients with recoverable cardiac functional reserve. Intermittent isolated ultrafiltration is valuable in partial responders because it improves quality of life and may be used as a bridge to heart transplantation. The high short-term mortality is consistent with the poor prognosis of advanced HF.
A new device, the Aquadex™ System 100 (CHF Solutions, Minneapolis), permits both the withdrawal of fluid and blood return through peripheral veins (see Figure 1) . However, central venous access remains an option. Fluid removal can range from 10 to 500ml/hour; blood flow can be set at 10-40ml/minute, and total extracorporeal blood volume is only 33ml. The device consists of a console, an extracorporeal blood pump, and venous catheters. The console controls blood removal rates and extracts ultrafiltrate at a user-set maximum rate. The device is designed to monitor the extracorporeal blood circuit and to alert the user to abnormal conditions. Ultrafiltrate drains into a bag. Blood is withdrawn from a vein through the withdrawal catheter. Tubing connects the withdrawal catheter to the blood pump. Blood passes through the withdrawal pressure sensor just before it enters the blood pump tubing loop.
During operation, the pump loop is compressed by rotating rollers that propel the blood through the tubing. After exiting the blood pump, blood passes through the air detector and enters the hemofilter. The hemofilter is bonded to a clip-on cartridge that mounts onto the ultrafiltrate pump raceway on the side of the console. Blood enters the filter through a port on the bottom, exits through the port at the top of the filter, and passes through the infusion pressure sensor before returning to the patient. Inside the hemofilter there is a bundle of hollow fibers. The ultrafiltrate passes through the fiber walls, fills the space between these fibers, and exits through a port near the top of the filter case. Ultrafiltrate then passes through a blood-leak detector. Ultrafiltrate sequentially passes through the ultrafiltrate pressure sensor, ultrafiltrate pump, and collecting bag that is suspended from the weight scale. Treatment can be performed by any nurse trained in the use of the device.
Three pilot trials of intermittent peripheral veno-venous ultrafiltration have been published. In the first study, in 21 fluid-overloaded patients, removal of It is also important to recognize the limitations of the UNLOAD trial. The treatment targets for both diuretics and ultrafiltration were not pre-specified.
Although treatment was not blinded, it is unlikely that a placebo effect influenced either weight loss or the improved 90-day outcomes associated with ultrafiltration. The possibility that standard care patients were inadequately treated is diminished by the observation that improvements in symptoms of heart failure, biomarkers, and quality of life were similar in the two treatment groups throughout the study. Furthermore, 43% of patients in the standard care group lost at least 4.5kg during hospitalization, a weight loss greater than that observed in 75% of patients enrolled in the Acute Decompensated Heart Failure National Registry. 2 Although the study did not include measurements of blood volume, plasma refill rate, interstitial salt and water, cardiac performance, or hemodynamics, ultrafiltration was not associated with excessive hypotension or renal or electrolyte abnormalities. The economic impact of ultrafiltration as an initial strategy for decompensated heart failure was also not addressed in this trial. While the costs associated with ultrafiltration during the index hospitalization may exceed those of intravenous diuretics, total cost over time may be lower due to decreased resource utilization for heart failure.
Conclusion
Of the ultrafiltration approaches described, the most practical are veno-venous ultrafiltration techniques in which isotonic plasma is propelled through the filter by an extracorporeal pump. These approaches avoid an arterial puncture, remove a predictable amount of fluid, are not associated with significant hemodynamic instability, and, in the case of peripheral veno-venous ultrafiltration, do not require specialized dialysis personnel. only if it can be proved that hypovolemia is absent.
Many questions regarding the use of ultrafiltration in HF patients remain unanswered and must be addressed in future studies. These include: optimal fluid removal rates in individual patients; the effects of ultrafiltration on cardiac remodeling; the influence of a low oncotic pressure occurring in patients with cardiac cachexia on plasma refill rates; and the economic impact of ultrafiltration to determine whether the expense of disposable filters is offset by the cost savings due to reduced re-hospitalization rates. ■
